Clinical Report: ELARA 24-Week Data Show Improvements in Wet AMD and DME
Overview
The ELARA study presents 24-week data demonstrating vision gains and reduced retinal thickness in patients with wet AMD and DME using flexible aflibercept 8 mg dosing. This study highlights the potential of a treat-and-extend protocol in previously treated eyes.
Background
Wet age-related macular degeneration (AMD) and diabetic macular edema (DME) are leading causes of vision loss. Effective management often requires ongoing treatment with anti-VEGF agents, and many patients experience persistent disease activity despite prior therapies. The ELARA study aims to evaluate the efficacy of flexible dosing of aflibercept 8 mg in this challenging patient population.
Data Highlights
| Condition | Vision Gain (letters) | Reduction in OCT (µm) |
|---|---|---|
| Wet AMD | 3 | 32 |
| DME | 3 | 50 |
Key Findings
- Patients with wet AMD experienced a vision gain of up to 3 letters.
- Patients with DME also showed a vision gain of approximately 3 letters.
- Reduction in retinal thickness was approximately 32 µm in the AMD cohort.
- In the DME cohort, retinal thickness reduced by up to 50 µm.
- The study involved eyes that had previously received anti-VEGF treatments but still exhibited disease activity.
- Future long-term data from the ELARA study will be available soon.
Clinical Implications
The findings from the ELARA study suggest that flexible dosing of aflibercept 8 mg may provide effective management for patients with wet AMD and DME who have previously been treated. This approach could potentially reduce treatment burden while maintaining visual acuity and anatomical improvements.
Conclusion
The ELARA study's 24-week data indicate promising outcomes for flexible aflibercept dosing in previously treated patients with wet AMD and DME. Ongoing research will further elucidate the long-term benefits of this treatment strategy.
References
- Retinal Physician, ELARA 24-Week Data Show Improvements in Wet AMD and DME, 2025 -- ELARA 24-Week Data Show Improvements in Wet AMD and DME
- Retinal Physician, Real-World Eylea HD Data Presented at ARVO, 2025 -- Real-World Eylea HD Data Presented at ARVO
- Ophthalmology, Clinical guidelines and consensus, 2025 -- Clinical guidelines and consensus
- Retinal Physician — SUBSPECIALTY NEWS
- retinal physician — Clinical Trial Update November/December 2025
- Retinal Physician — SUBSPECIALTY NEWS: Pegcetacoplan gets priority review, Eva Nexus injector cleared, Eylea extended dosing under review, and more.
- Ophthalmology | Vol 132, Issue 4, Pages A1-A20, P1-P344, e1-e78, 375-506 (April 2025) | ScienceDirect.com by Elsevier
- Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial - ScienceDirect
- ELARA 24-Week Data Show Improvements in Wet AMD and DME | Retinal Physician
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
